Key Highlights

  • Thermo Fisher Scientific (NYSE:TMO) reports before the open on Wednesday, October 21, 2026, with consensus earnings of USD 6.40 per share and revenue of USD 11.93 billion, after closing the October 19 session at USD 679.38, down 1.54%.
  • RingCentral (NYSE:RNG) reports after the close on Thursday, October 22, 2026, after a 4.97% rebound to USD 79.19 on October 19, with analysts split between six Buy and nine Hold ratings and a mean target near USD 57.64.
  • Centene (NYSE:CNC) reports at about 6:00 a.m. ET on Tuesday, October 27, 2026, with 2026 adjusted earnings guidance above USD 4.80 per share and a second-quarter Medicaid health benefits ratio of 93.9%.
  • Microsoft (NASDAQ:MSFT) reports on Wednesday, October 28, 2026, with consensus earnings of USD 4.73 per share and revenue near USD 90.65 billion, and Morgan Stanley wants Azure growth in the mid-40% range.

Thermo Fisher Scientific (NYSE:TMO): Life Science Tools Bellwether

The company is the first among life science tools peers to report this season, so its results set the tone for the group. Consensus expects earnings of USD 6.40 per share and revenue of USD 11.93 billion against USD 11.12 billion a year earlier, or growth of about 7%, a figure that is simple arithmetic on two published numbers. Last quarter revenue was USD 11.99 billion, up 10.5%, with a beat on organic growth. Analysts say the sector is helped by improving demand from pharma and biotech customers. Thermo Fisher Scientific (NYSE:TMO) fell 1.54% on October 19, so the shares enter the report slightly lower. The 52-week high is implied at about USD 704 from the 3.5% gap. The company sells instruments, consumables, software and services to labs, and its bioprocessing and clinical research units earn recurring revenue when customers run more experiments and manufacture more drugs. The Clario acquisition added digital endpoint data for clinical trials and tracked above expectations in the second quarter. The filtration and separation business bought from Solventum for about USD 4.0 billion in cash is expected to produce USD 125 million of adjusted operating income from synergies by the fifth year after closing. Strategists have also pointed to a rotation out of artificial intelligence names into healthcare, and life science tools have beaten the rest of the sector this year.

RingCentral (NYSE:RNG): Cloud Communications Rebound

No same-day catalyst was found for October 19, when RingCentral (NYSE:RNG) rebounded 4.97% to USD 79.19. The move followed a fall of 5.63% on the prior session and a 7-day decline of 4.83%, after a rise of about 173% this year, so it looks like a bounce ahead of earnings, though the exact trigger is not known. On October 13 the company announced a strategic partnership with Allnet.Italia, its first wholesale partnership in Italy, giving thousands of local resellers an AI-first cloud communications platform to sell. The shares are 3.3% below their 52-week high, implied at about USD 81.9 from published market data, simple arithmetic. Second-quarter revenue grew 5.9% to USD 657 million, about 1% above estimates, and billings, a measure of cash collected from customers, came in at USD 695 million. Full-year earnings guidance was raised, and management is pushing Agentic Voice AI on its message, video and phone platform. Operating margin on a trailing basis was 6.7%, up about 4 points in two years. The shares trade near 2.5 times forward sales.

Centene (NYSE:CNC): Managed Care Turnaround

No same-day catalyst was found for October 19, when Centene (NYSE:CNC) slipped 0.77% to USD 68.63. The recent lift came on October 13, when shares closed up 2.8% at USD 68.88 and had gained about 6.6% across the days that followed news of a performance-based Gold Card prior authorization program, the redemption of USD 568.66 million of 4.25% notes due 2027 and an Ambetter primary care collaboration. The deeper driver is the turnaround: first-quarter adjusted earnings were USD 3.37 per share against estimates near USD 2.13, and 2026 guidance has been raised twice. The 52-week high is implied at about USD 71.2 from the 3.6% gap, simple arithmetic on published market data. The company serves Medicaid, Medicare and ACA Marketplace members, with revenue of about USD 92.6 billion from Medicaid, USD 40.4 billion from Medicare and USD 40.7 billion from Commercial in published market data. Second-quarter premium and service revenue rose 4% to USD 44.4 billion. The Marketplace pretax margin outlook for 2026 rose to 4.5% to 5%, helped by repricing, and the quarter included about USD 180 million of favorable risk adjustment development that is unlikely to repeat. Management said about USD 0.50 per share of 2026 earnings will not recur in 2027.

Microsoft (NASDAQ:MSFT): Azure and Copilot in Focus

No single-day catalyst was found for October 19, when Microsoft (NASDAQ:MSFT) gained 0.84% to USD 533.52. The driver is a run into earnings. Morgan Stanley noted that shares have gained about 40% since the July report, helped by better results and initial fiscal 2027 guidance that pointed to durable strength in core growth businesses, and warned of a higher bar. It expects Azure to grow in the mid-40% range, better Microsoft 365 and Copilot monetization and disciplined operating expenses. In July, Azure and other cloud services grew 43% and intelligent cloud revenue rose 32%. The 52-week high is implied at about USD 553.4 from the 3.6% gap, simple arithmetic on published market data. Azure growth depends on how fast data center capacity comes online: Morgan Stanley estimates about 3.25 gigawatts was added in fiscal 2026 and about 4.25 gigawatts more will follow in fiscal 2027. The company has introduced its Maia 300 inference chip to improve infrastructure efficiency, and paid Copilot seats passed 30 million. Consensus expects earnings of USD 4.73 per share and revenue of about USD 90.65 billion, with Morgan Stanley at USD 90.24 billion. Partner checks point to continued upgrades from Microsoft 365 E3 to E5, while consumption-based Copilot usage is still early.

Where Things Stand

The reports arrive in a tight sequence from October 21 to October 28, testing life science tools, cloud communications, managed care and large-cap software. All four sit within 3.6% of 52-week highs, so expectations are elevated. RingCentral (NYSE:RNG) has the widest gap between its price and analyst targets. Centene (NYSE:CNC) has the cleanest margin recovery story, with about USD 0.50 per share of 2026 earnings not expected to recur in 2027. Guidance is likely to matter more than the quarter, and estimates differ by provider. This is not investment advice.